Edition 2/2019: 7 Steps for Success in Tender Management

Change and taking action usually starts with either inspiration or desperation. You could be inspired and intrigued by the opportunities and possibilities that something offers. Or you are desperate and disappointed about the fact that things do not go the way you want them to go and you are almost forced to change something. This also applies to Tendering.

 The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story.  These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions.

With 25% of the pharmaceutical market worldwide going through some form of T&C, you are far from alone. We expect, in both developed and emerging countries that trend to not only continue, but increase. Consequently, the importance for Life Sciences companies to build a succesful tendering and contracting governance globally increases as well. 

With public procurement growing across industries, Life Sciences companies are no exception to the rule. Indeed, 25% of the pharmaceutical market is now considered to be traded through some form of tender. Tenders are a specific form of centralized procurement where government or any level of health authorities are enforcing competition for a product.

Presentation of Manu Carricano on the 13th EPP Global Pricing Forum.

CLICK AND WATCH THE VIDEO BELOW

Edition 4/2018 : GCC-DR Price Harmonization and the Effects of ERP

Through the Gulf Central Committ ee for Drug Registration (GCC-DR), Saudi Arabia, Bahrain, Oman, and other Arabian Peninsula nations have sought to rein in the rising costs of drugs through price harmonization. The inter-peninsular reference pricing effect has incited price cuts for the GCC-DR countries, most noticeably since 2014, when the harmonization effort went into full effect.  While the GCC-DR countries rely on one another and, most often, Saudi Arabia, to attain the best pricing for a drug, these countries simultaneously use external reference pricing (ERP ) to seek the lowest price possible for a medicine. Recently, South Korea has been officially added to Saudi Arabia’s list of published reference countries. The Asian country is known for having low cost drugs; in turn, Saudi’s trans-continental reliance on South Korea – albeit done inconsistently – has helped to lower the cost of expensive pharmaceuticals, particularly
biologics for cancer.

The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story.  These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions.

13 th EPP European & Global Pricing Forum

13 th EPP European & Global Pricing Forum

13 th EPP European & Global Pricing Forum

13 th EPP European & Global Pricing Forum

13 th EPP European & Global Pricing Forum